Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

doi:10.3748/wjg.v22.i12.3418

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10169)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

618

WORD

283

HTML

5362

Figures (1-2)

240

Tables (1-4)

222

Sum=6725

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1348

Download

2096

Sum=3444

Mar 28, 2016 (publication date) through Dec 14, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 28, 2016; 22(12): 3418-3431
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3418

Table 4 Overall on-treatment safety in GT1-infected patients

Event, n (%)	*DCV + pegIFN/RBV (n =* 402)**	*TVR + pegIFN/RBV (n =* 200)¹**
Death	1 (0.2)²	1 (0.5)²
SAEs	26 (6.5)²	20 (10.0)²
AEs leading to discontinuation of any study drug	28 (7.0)²	37 (18.5)²
AEs leading to discontinuation of all 3 study drugs	25 (6.2)	25 (12.5)
AEs (grade 1-4) ≥ 20%
Fatigue	140 (34.8)	81 (40.5)
Headache	137 (34.1)	57 (28.5)
Asthenia	109 (27.1)	53 (26.5)
Pruritus	107 (26.6)	75 (37.5)
Anemia	96 (23.9)	99 (49.5)
Rash	93 (23.1)	69 (34.5)
Nausea	88 (21.9)	74 (37.0)
Neutropenia	87 (21.6)	27 (13.5)
Alopecia	86 (21.4)	32 (16.0)
Influenza-like illness	85 (21.1)	38 (19.0)
Dry skin	84 (20.9)	34 (17.0)
Pyrexia	80 (19.9)	42 (21.0)
Grade 3 or 4 emergent laboratory abnormalities
Hemoglobin	26 (6.5)	41 (20.5)
Absolute neutrophil count	104 (25.9)	41 (20.5)
Lymphocytes	67 (16.7)	44 (22.0)
^{Platelet count}	15 (3.7)	8 (4.0)
ALT	3 (0.7)	4 (2.0)
AST	7 (1.7)	1 (0.5)
Total bilirubin	4 (1.0)	6 (3.0)
Serum creatinine increased	1 (0.2)	0

¹n = 198 for grade 3/4 laboratory abnormalities;

²Further information provided in supplementary material. AE: Adverse event; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; DCV: Daclatasvir; GT: Genotype; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; SAE: Serious adverse event; TVR: Telaprevir.

Citation: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431
URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3418.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i12.3418